Related Experiment Video

Updated: Jun 21, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.5K

Macrophages participate in doxorubicin-induced cardiac damage

Federica Andrea Cerasuolo1, Jessica Gambardella1, Gaetano Santulli2

  • 1Department of Advanced Biomedical Science, University of Naples Federico II, 80138 Naples, Italy.

Vascular Pharmacology
|July 10, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K
Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens
07:25

Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens

Published on: December 17, 2019

8.0K

Related Experiment Videos

Last Updated: Jun 21, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.5K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K
Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens
07:25

Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens

Published on: December 17, 2019

8.0K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564

Articles linked to this work by shared authors, journal, and citation graph.

Beta-blockers in patients with uncomplicated arterial hypertension: data from the Campania Salute Network Registry.

European heart journal. Quality of care & clinical outcomes·2026

Early mitophagy defects and impaired mitochondrial energy metabolism drive target organ damage progression: lessons from the Fabry heart.

bioRxiv : the preprint server for biology·2026

The Role of L-Arginine and Liposomal Vitamin C Supplementation as an Adjunct in Seasonal Respiratory Viral Infection Recovery.

Advances in respiratory medicine·2026

A six-year longitudinal study identifies a statin-independent association between low LDL-cholesterol and risk of type 2 diabetes.

Cardiovascular diabetology·2025

Abdominal Aorta Remodeling in Hypertensive Patients: The Campania Salute Network.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension·2025

Dual modulation of lipid and glucose metabolism by a nutraceutical combination in patients at cardiometabolic risk: results from a multicenter randomized controlled trial.

Cardiovascular diabetology·2025

NLRP3 inflammasome-NETosis crosstalk in hypertensive cardiac remodeling: Cellular mechanisms and therapeutic opportunities.

Vascular pharmacology·2026

TUG-891-mediated FFAR4 activation attenuates vascular remodeling via suppression of aberrant browning and lipolysis in perivascular adipose tissue.

Vascular pharmacology·2026

Aquaporin-1 facilitates the transport of hydrogen peroxide and nitric oxide during endothelium-dependent vasorelaxation.

Vascular pharmacology·2026

Pan-peroxisome proliferator-activated receptor agonist IVA337 alleviates secondary lymphedema via inhibiting TGFβ/SMAD2/3 signaling pathway.

Vascular pharmacology·2026

Multi-omics and experimental validation reveal the proliferative mechanism of ACSL4 in pulmonary hypertension and identify potential FDA-approved drugs via in silico screening.

Vascular pharmacology·2026

Formoterol fumarate attenuates atherosclerosis and improves cardiometabolic dysfunction in ApoE-deficient mice.

Vascular pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us